Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET

Rhea-AI Summary

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced participation in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET. CEO Raj Kannan, CFO Peter Lang, and CMO Dr. Gary Sternberg will discuss the company’s ophthalmic therapies for eye diseases, including open-angle glaucoma and diabetic macular edema. The event will be webcasted and available for replay until July 11, 2022. Learn more about Aerie's products, Rhopressa® and Rocklatan®, which are FDA-approved treatments for elevated intraocular pressure.

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will participate in a fireside chat at the 21^st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. Eastern Time.

Details:
Date:				April 12, 2022
Fireside chat time:				3:00 p.m. ET
Webcast:				http://investors.aeriepharma.com
Replay Availability:				Until July 11, 2022

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005972/en/

Media:

Carolyn McAuliffe

cmcauliffe@aeriepharma.com

(949) 526-8733



Investors:

LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.

Hans Vitzthum

hans@lifesciadvisors.com

(617) 430-7578

Source: Aerie Pharmaceuticals, Inc.

FAQ

When is Aerie Pharmaceuticals participating in the Needham Virtual Healthcare Conference?

Aerie Pharmaceuticals will participate in the Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.

Who are the speakers from Aerie Pharmaceuticals at the conference?

The speakers include CEO Raj Kannan, CFO Peter Lang, and CMO Dr. Gary Sternberg.

How can I watch the Aerie Pharmaceuticals fireside chat?

The fireside chat will be available via webcast on Aerie's investor relations website.

What products does Aerie Pharmaceuticals offer for eye diseases?

Aerie Pharmaceuticals offers Rhopressa® and Rocklatan®, both FDA-approved for treating elevated intraocular pressure.

Until when can I access the replay of the Aerie Pharmaceuticals conference?

The replay of the conference will be available until July 11, 2022.